Foghorn Therapeutics Inc. SEC Filings

Foghorn Therapeutics Inc. furnished an investor presentation as Exhibit 99.1 under Item 7.01 (Regulation FD). The presentation is dated November 2025 and is intended for meetings with or presentations to investors. The materials are being furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference except as expressly stated.

Foghorn Therapeutics (FHTX) reported Q3 2025 results. Collaboration revenue was $8,153,000, modestly above last year. Operating expenses declined year over year as research and development fell to $20,002,000 and general and administrative to $6,652,000. The company posted a net loss of $15,849,000, or $0.25 per share.

Cash and cash equivalents were $89,334,000 and marketable securities were $90,944,000 as of September 30, 2025. Deferred revenue totaled $258,401,000 (current $65,299,000; long‑term $193,102,000), reflecting ongoing performance under the Eli Lilly collaboration. Interest income contributed $2,032,000 in the quarter, and weighted average shares outstanding were 63,029,293. Management states existing cash, cash equivalents and marketable securities will fund operations for at least 12 months.

The Lilly-partnered SMARCA2 program (FHD‑909) remains in early clinical development with cost sharing in place; collaboration revenue recognized depends on progress and costs incurred over time.

Foghorn Therapeutics (FHTX) furnished a press release announcing financial results for the quarter ended September 30, 2025. The materials were provided as Exhibit 99.1.

The company also disclosed that Chief Financial Officer Kristian Humer will resign effective November 14, 2025. The resignation was described as to pursue other opportunities and not due to any disagreement regarding operations, policies, practices, financial controls, or audit procedures. Foghorn has begun a search for a replacement.

Additionally, Foghorn furnished an investor presentation dated November 2025 as Exhibit 99.2.

Foghorn Therapeutics (FHTX) filed an 8-K announcing pipeline updates for its Selective ARID1B, Selective CBP, and Selective EP300 degrader programs. On October 30, 2025, the company hosted a conference call and webcast to review these updates, and furnished the related presentation as Exhibit 99.1 under Regulation FD.

Foghorn also issued a press release on the same date, attached as Exhibit 99.2 and incorporated by reference. The furnished materials are not deemed filed for liability purposes under Section 18 of the Exchange Act. The disclosure includes customary forward-looking statements language referencing clinical trials, product candidates, and risk factors in the company’s most recent Form 10-K.

Foghorn Therapeutics (FHTX) Q2-25 10-Q highlights:

• Revenue: Collaboration income with Eli Lilly rose 10% YoY to $7.6 m; H1-25 revenue up 13% to $13.5 m.
• Expenses: R&D fell 8% to $21.8 m and G&A fell 6% to $6.9 m, driving a 15% narrower operating loss of $21.1 m.
• Net loss: Q2 loss improved to $17.9 m (-$0.28/sh) from $23.0 m (-$0.45/sh) last year; H1 loss narrowed to $36.8 m (-$0.58/sh).
• Liquidity: Cash & cash equivalents $72.6 m; marketable securities $126.1 m; combined liquid resources $198.7 m. Management expects runway ≥12 months despite $45 m operating cash burn in H1.
• Balance sheet: Deferred revenue declined to $266.6 m as collaboration work progresses; total liabilities $302.9 m exceed assets $226.2 m, producing a $76.7 m shareholders’ deficit.
• Operations: FHD-909 (SMARCA2) transitioned to Lilly with 50/50 cost share; FHD-286 development discontinued (2024). New 10-year Watertown lease signed; Cambridge lease partially reduced, lowering future obligations by $8.5 m.

Key takeaways: Expense discipline and steady milestone revenue trimmed losses, but the pre-commercial company remains cash-burning and carries a negative equity position. Progress of the Lilly collaboration and access to additional capital remain critical catalysts.